This guideline article comprehensively examines pharmacological
approaches and psychosocial interventions for depression subtypes and
special patient groups in the treatment of major depressive disorder
(MDD), along with their levels of evidence. Among depression subtypes,
the approach with the highest level of evidence for psychotic depression
is the combination of an antipsychotic with an antidepressant, whereas
in atypical depression, despite a lack of new research, monoamine
oxidase inhibitors (MAOI) have shown the most prominent efficacy
compared to placebo.